Star Sports Medicine Co., Ltd. has released its 2025 financial and governance proposals ahead of the annual shareholders’ meeting scheduled for 26 June 2026 in Beijing.
Financial snapshot • Total assets at end-2025: RMB 764.00 million • Equity attributable to owners: RMB 609.00 million • Management reports “steady” year-on-year growth in both revenue and profit; cash flow described as “relatively sufficient.” • No dividend proposed for 2025 to preserve cash for operations and risk management.
Auditor and budget • Ernst & Young Hua Ming LLP recommended for re-appointment for 2026 with an annual fee of RMB 3.00 million–3.50 million. • 2026 budgeting continues a “strict economy” approach, targeting cost controls, market expansion and higher profit.
Governance overhaul • Proposal to abolish the Board of Supervisors; its statutory oversight functions would transfer to the Board’s Audit Committee. Existing supervisors’ terms will end upon shareholder approval. • Comprehensive amendments to the Articles of Association and procedural rules reflect the new structure.
Capital mandates • Share repurchase mandate: authorises buy-back of up to 10% of issued H shares (currently 54.83 million), with discretion to cancel or hold the shares as treasury stock. • General issuance mandate: permits issuance or transfer of up to 20% of existing share capital. • Both mandates run until the next AGM.
Director and executive compensation • Executive and non-executive directors: no additional remuneration for directorships. • Independent non-executive directors: annual allowance of RMB 100,000 (pre-tax). • Senior-management salaries remain unchanged under existing labour contracts.
Key AGM details • Record date: 22 June 2026; register closed 23–26 June. • Venue: Weilaige Conference Room, ZKML Building, Beijing. • Proxy forms due by 10:00 a.m. on 25 June 2026.
Share capital • Issued share capital stands at 54,831,344 H shares with a nominal value of RMB 1.00 each.
All resolutions, including financial statements, repurchase and issuance mandates, auditor re-appointment and governance amendments, will be put to shareholder vote by poll at the AGM.